Periodontitis
Conditions
Brief summary
This randomized, double-blind, placebo-controlled 2-arm, parallel group clinical trial is designed to evaluate the impact of the regular consumption of a polyphenol-containing Maritime Pine (Pinus pinaster) bark extract (Pycnogenol®) on clinical signs of gingival inflammation in a cohort of periodontal aftercare patients
Detailed description
Polyphenols are natural compounds produced by plants that have various functions, such as defence against microbial pathogens or protection against UV light. Based on their antioxidant activity, a soothing or preventive effect of polyphenols on various inflammatory diseases has been suspected. There is evidence of an anti-inflammatory effect of polyphenols in manifest periodontitis as well as antibacterial properties of these compounds. In addition, it is discussed that dietary polyphenols intervene in mechanisms involved in the pathophysiology of arteriosclerotic changes and their progression. This randomized, double-blind, placebo-controlled 2-arm, parallel group clinical trial is designed to evaluate the impact of the regular consumption of a polyphenol-containing Maritime Pine (Pinus pinaster) bark extract (Pycnogenol®) on clinical signs of gingival inflammation in a cohort of periodontal aftercare patients
Interventions
DIETARY_SUPPLEMENTPycnogenol
daily consumption of a pycnogenol-containing capsule
DIETARY_SUPPLEMENTPlacebo
Daily consumption of a placebo capsule
Sponsors
University of Wuerzburg
Wuerzburg University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
The experimental pine bark dietary supplement is packaged in neutral capsules, which are dispensed to the study patients in bottles with code labels.
Intervention model description
randomized, double-blind, placebo-controlled 2-arm, parallel group clinical trial
Eligibility
Sex/Gender
ALL
Age
35 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* number of teeth ≥ 10 * age ≥ 35 ≤ 90 years * body mass index (BMI) ≥ 20 ≤ 30 * history of periodontal disease and inclusion in a regular scheme of supportive periodontal therapy (regularly repeated subgingival biofilm removal 2-4 x/year) * minimum of 10% probing sites displaying bleeding on probing
Exclusion criteria
* manifestation of inflammatory oral mucosal diseases other than gingivitis * xerostomia (stimulated salivary flow ≤ 0.1 ml/minute) * inability to perform regular oral home care * inability to follow the study protocol due to intellectual or physical handicaps * history of malignancy, radiotherapy, or chemotherapy for malignancy in the past 5 years * current pregnancy * acute infections such as HIV * manifestation of metabolic bone disease * use of antibiotics and/or anti-inflammatory medications within 4 weeks prior to screening. * current orthodontic therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bleeding on Probing (BoP) | 6 months | Bleeding on Probing (BoP) is defined as the appearance of a bleeding spot within 30 seconds after gently probing the evaluated periodontal pocket by inserting the periodontal probe up to the probable bottom of the pocket. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Plaque Control Record (PlaCR) | 6 months | Plaque Control Record (PlaCR) is defined as the percentage of assessed supragingival tooth surfaces covered by bacterial plaque. The presence of bacterial plaque is visually assessed after staining the tooth surfaces with a plaque staining agent. |
| Compositional changes within the intestinal microbiota | 6 months | Compositional changes within the intestinal microbiota between baseline and end of the study are assessed by Next Generation Whole Genome Sequencing on a species level |
| Compositional changes within the oral microbiota | 6 months | Compositional changes within the oral microbiota between baseline and end of the study are assessed by Next Generation Whole Genome Sequencing on a species level |
| Change in periodontally inflamed surface area (PISA) | 6 months | PISA is calculated using the recorded pocket depths and bleeding on probing scores at each evaluated tooth at baseline and at the end of the trial at 6 months. |
| Change in salivary polyphenol concentration | 3 months | Saliva samples for the analysis of salivary polyphenols levels are taken at baseline and at 3 months |
| Gingival Index GI | 6 months | Gingival Index will be recorded visually according to the modification of the original GI. |
| Change in salivary levels of cytokines, cytokine inhibitors, matrix metalloproteinases and MMP inhibitors | 6 months | Saliva samples are taken at baseline and at the end of the study at 6 months for the analysis of salivary interleukin (IL) 1ß, IL-6, IL-8, IL-31, matrix metalloproteinase (MMP)-8, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 and Histatin 5 levels. |
| Change in serum levels of cytokines, cytokine inhibitors, matrix metalloproteinases and MMP inhibitors | 6 months | Blood samples are taken at baseline and at the end of the study at 6 months for the analysis of serum interleukin (IL) 1ß, IL-6, IL-8, IL-31, matrix metalloproteinase (MMP)-8, MMP-9, and tissue inhibitor of metalloproteinase (TIMP)-1 levels. |
| Change in pulse wave velocity | 3 months | Pulse wave velocity (m/sec) is measured at baseline and at 3 months |
| Change in central aortal pulse pressure | 3 months | Central aortal pulse pressure (mmHg) is measured at baseline and at 3 months |
| Change in peripheral systolic and diastolic blood pressure | 3 months | Peripheral systolic and diastolic blood pressure (mmHg) is measured at baseline and at 3 months. |
| Change in polyphenol serum concentration | 3 months | Blood samples for the analysis of polyphenol serum levels are taken at baseline and at 3 months |
Countries
Germany
Outcome results
None listed